Objective: To compare the maturation of speech-evoked N170 components of cortical auditory evoked potentials with that of tone-evoked N1 components. Patients and Methods: Cortical auditory evoked potentials to speech and tone stimuli were derived in 42 children from age 4 to 14 years. The N170 was derived from the difference curve of responses to monosyllabic words with initial consonant-to-vowel transitions and their intensity-equivalent noise signals. Results: The incidence of N1 increased from 71% below age 9 to 91% above, that of N170 tended to increase from 40 to 67% above. From age 9, adult-like morphologies of the difference waveforms were found and the time constants of N1 and N170 latency maturation were nearly identical. Conclusion: The N170 component is interpreted as a response to speech-specific acoustic changes such as the consonant-vowel transition. The late appearance of N170 indicates an electrophysiological correlate of speech perception that continues to develop into adolescence. Its clinical application, however, is limited due to the low incidence of N170.

Keywords:
Cortical auditory evoked potential, Maturation, Speech processing, Mismatch negativity
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.